<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196401</url>
  </required_header>
  <id_info>
    <org_study_id>17-269</org_study_id>
    <nct_id>NCT03196401</nct_id>
  </id_info>
  <brief_title>A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma</brief_title>
  <official_title>A Pilot Study to Evaluate for the Abscopal Effect of Durvalumab (Anti-PD-L1) in Combination With Definitive Radiation Therapy in Solitary Bone Plasmacytoma With Limited Clonal Bone Marrow Plasmacytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate whether the combination of immune therapy and radiation&#xD;
      therapy to plasmacytoma that can stimulate the immune system to attack and eliminate the&#xD;
      abnormal cells in the bone marrow and perhaps delay or prevent the cancer from worsening.&#xD;
      This study will evaluate whether the immune system responds to the combination of radiation&#xD;
      with immunotherapy. It is possible that that the combination of immune therapy and radiation&#xD;
      may not make any difference in whether or not the patient will develop multiple myeloma in&#xD;
      the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    FDA recommendation&#xD;
  </why_stopped>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label, single center, single-arm pilot study of checkpoint blockade therapy (anti-PD-L1) plus radiation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response assessment</measure>
    <time_frame>up to 36 months from start of cycle 1</time_frame>
    <description>Disease assessments are made according to IMWG criteria including criteria for minimal residual disease</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Solitary Bone Plasmacytoma</condition>
  <arm_group>
    <arm_group_label>Durvalumab Plus Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>durvalumab 1500mg administered intravenously every 28 days, for a total of six doses</description>
    <arm_group_label>Durvalumab Plus Radiation Therapy</arm_group_label>
    <other_name>(MEDI4736)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting</description>
    <arm_group_label>Durvalumab Plus Radiation Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically confirmed plasmacytoma amenable for biopsy&#xD;
&#xD;
          -  Detectable clonal bone marrow plasma cells by multicolor flow cytometry and less than&#xD;
             10% clonal plasma cells in a bone marrow biopsy by immunohistochemistry, morphology,&#xD;
             or flow cytometry.&#xD;
&#xD;
          -  Clinically safe to delay radiation for at least 2 weeks.&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Anticipated lifespan greater than 3 month.&#xD;
&#xD;
          -  Adequate organ function, as defined below:&#xD;
&#xD;
               -  Total bilirubin within normal ranges unless associated with hepatobiliary&#xD;
                  metastases or Gilbert syndrome, then total bilirubin ≤ 2 x ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Able and willing to give valid written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis with the&#xD;
             exception of a prior episode that has resolved or diverticulosis, celiac disease,&#xD;
             irritable bowel disease, or other serious gastrointestinal chronic conditions&#xD;
             associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome&#xD;
             [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid&#xD;
             arthritis; hypophysitis, uveitis; etc) within the past 3 years prior to the start of&#xD;
             treatment. The following are exceptions to this criterion: subjects with vitiligo or&#xD;
             alopecia; subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on&#xD;
             hormone replacement; or subjects with psoriasis not requiring systemic treatment.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days prior to first&#xD;
             dose of durvalumab. The following are exceptions to this criterion: intranasal,&#xD;
             inhaled, topical or local steroid injections (eg. intra-articular injection); steroids&#xD;
             as premedication for hypersensitivity reactions; systemic corticosteroid at&#xD;
             physiologic doses not to exceed 10mg/day of prednisone or equivalent.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of&#xD;
             active hepatitis B virus (HBV).&#xD;
&#xD;
          -  History of hypersensitivity to durvalumab or any excipient&#xD;
&#xD;
          -  History of hypersensitivity to the combination or comparator agent (If applicable)&#xD;
             Receipt of live attenuated vaccination within 30 days prior the first dose of&#xD;
             durvalumab.&#xD;
&#xD;
          -  Female subjects who are pregnant, breast-feeding or female patients of reproductive&#xD;
             potential who are not employing an effective method of birth control from starting&#xD;
             dose of durvalumab (Cycle 1 Day 1), including dosing interruptions through 90 days&#xD;
             after receipt of the last dose of durvalumab. Refrain from egg cell donation while&#xD;
             taking durvalumab and for at least 90 days after the last dose of durvalumab.&#xD;
&#xD;
          -  Male subjects who are not employing an effective method of birth control from starting&#xD;
             dose of durvalumab (Cycle 1 Day 1), including dosing interruptions through 90 days&#xD;
             after receipt of the last dose of durvalumab. Refrain from sperm donation while taking&#xD;
             durvalumab and for at least 90 days after the last dose of durvalumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Lesokhin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>August 2, 2018</last_update_submitted>
  <last_update_submitted_qc>August 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Durvalumb</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Clonal Bone Marrow Plasmacytosis</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>17-269</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

